Silence Therapeutics plc (Silence Therapeutics) is a United Kingdom-based company engaged in the research and development of pharmaceutical products. Silence Therapeutics is engaged in the discovery, development and delivery of ribonucleic acid interference (RNAi) therapeutics for the treatment of diseases. The Company’s products include Atu027, which is in a phase IIa clinical trial and Atu111, which is in Phase I of pre-clinical trial stage. Atu027 is Silence’s leading short interfering RNA (siRNA) therapy. It uses the Company’s AtuPLEX and AtuRNAi technologies to deliver siRNA to the endothelial cells of the vascular system, targeting the expression of the protein PKN3, a key factor in cancer progression and metastasis.